{
  "name": "sarek-somatic-variants",
  "title": "Sarek Somatic Variant Calling",
  "description": "Tumor-normal somatic variant calling from WGS/WES. Detects cancer mutations using Mutect2, Strelka2, and other somatic callers with best-practice tumor analysis. Samplesheet format: `sample,lane,fastq_1,fastq_2`",
  "version": "1.0.0",
  "engineType": "NEXTFLOW",
  "command": "nextflow run nf-core/sarek --input ${input} --outdir ${outdir} --genome ${genome} --tools ${tools} -r 3.5.1 ",
  "imageUrl": "https://raw.githubusercontent.com/nf-core/sarek/master/docs/images/nf-core-sarek_logo_light.png",
  "content": "<h2><strong>Sarek Somatic Variant Calling</strong></h2><p><strong>Somatic variant calling</strong> identifies mutations acquired in cancer cells that are not present in the patient's germline DNA. By comparing tumor and matched normal tissue, we detect driver mutations, resistance variants, and therapeutic targets.</p><h3><strong>What are Somatic Variants?</strong></h3><blockquote><p><strong>Somatic mutations</strong> arise in specific cells/tissues during a person's lifetime (not inherited). In cancer, these mutations drive tumor growth, metastasis, and drug resistance. Unlike germline variants, somatic mutations cannot be passed to offspring.</p></blockquote><h3><strong>Why Tumor-Normal Analysis?</strong></h3><ul><li><strong>Distinguish Somatic from Germline</strong>: Mutations in tumor but not normal = cancer-specific</li><li><strong>Reduce False Positives</strong>: Filter out common germline variants</li><li><strong>Detect Driver Mutations</strong>: TP53, KRAS, EGFR, BRAF, PIK3CA</li><li><strong>Identify Actionable Targets</strong>: Mutations treatable with targeted therapy</li><li><strong>Tumor Evolution</strong>: Track clonal architecture, heterogeneity</li><li><strong>Resistance Mechanisms</strong>: Acquired mutations after treatment</li></ul><h3><strong>Pipeline Workflow</strong></h3><ol><li><strong>Preprocessing</strong>: Align tumor + normal with BWA-MEM2</li><li><strong>Mark Duplicates</strong>: Remove PCR artifacts</li><li><strong>Base Quality Recalibration</strong>: GATK BQSR</li><li><strong>Somatic Variant Calling</strong>: Mutect2, Strelka2, Manta (SVs)</li><li><strong>Filtering</strong>: Panel of normals, contamination estimation</li><li><strong>Annotation</strong>: VEP adds clinical significance, hotspots</li><li><strong>CNV Calling</strong>: CNVkit, ASCAT for copy number alterations</li><li><strong>QC Report</strong>: MultiQC with tumor purity, ploidy estimates</li></ol><h3><strong>Somatic Variant Callers</strong></h3><p><strong>GATK Mutect2</strong> (recommended):</p><ul><li>Gold standard for tumor-normal calling</li><li>Uses panel of normals (PoN) to filter artifacts</li><li>Estimates contamination, allele fractions</li><li>Detects low-frequency variants (5-10% VAF)</li></ul><p><strong>Strelka2</strong>:</p><ul><li>Fast, accurate somatic SNV/indel caller</li><li>Good sensitivity for low-VAF variants</li><li>Lower resource usage than Mutect2</li></ul><p><strong>Manta</strong>:</p><ul><li>Structural variant (SV) caller</li><li>Detects deletions, duplications, inversions, translocations</li><li>Important for gene fusions (BCR-ABL, EML4-ALK)</li></ul><p><strong>ASCAT / CNVkit</strong>:</p><ul><li>Copy number variation (CNV) detection</li><li>Estimates tumor purity, ploidy</li><li>Identifies amplifications (ERBB2, MYC) and deletions (CDKN2A)</li></ul><h3><strong>Scientific Applications</strong></h3><p><strong>Precision Oncology</strong>:</p><ul><li>Identify actionable mutations for targeted therapy</li><li><strong>EGFR mutations</strong>: Lung cancer \u2192 erlotinib, osimertinib</li><li><strong>BRAF V600E</strong>: Melanoma \u2192 vemurafenib, dabrafenib</li><li><strong>HER2 amplification</strong>: Breast cancer \u2192 trastuzumab</li><li><strong>KRAS G12C</strong>: Colorectal, lung \u2192 sotorasib</li></ul><p><strong>Tumor Profiling</strong>:</p><ul><li>Molecular subtyping (luminal, basal, HER2+)</li><li>Mutational signatures (UV, tobacco, APOBEC, MMR deficiency)</li><li>Tumor mutational burden (TMB) \u2192 immunotherapy response</li><li>Microsatellite instability (MSI) \u2192 Lynch syndrome, immunotherapy</li></ul><p><strong>Clonal Evolution</strong>:</p><ul><li>Primary tumor vs metastasis</li><li>Pre-treatment vs post-relapse</li><li>Clonal vs subclonal mutations</li><li>Tumor heterogeneity</li></ul><p><strong>Liquid Biopsy</strong>:</p><ul><li>Circulating tumor DNA (ctDNA) in blood</li><li>Minimal residual disease monitoring</li><li>Early detection of recurrence</li></ul><h3><strong>Key Cancer Genes</strong></h3><blockquote><p><strong>Tumor Suppressors</strong> (loss-of-function):</p><ul><li><strong>TP53</strong>: Mutated in 50% of cancers</li><li><strong>PTEN</strong>: PI3K pathway inhibitor</li><li><strong>RB1</strong>: Cell cycle regulator</li><li><strong>APC</strong>: Colorectal cancer</li></ul><p><strong>Oncogenes</strong> (gain-of-function):</p><ul><li><strong>KRAS, NRAS, HRAS</strong>: RAS pathway (30% of cancers)</li><li><strong>EGFR</strong>: Receptor tyrosine kinase (lung, glioblastoma)</li><li><strong>BRAF</strong>: MAPK pathway (melanoma, colorectal)</li><li><strong>PIK3CA</strong>: PI3K pathway (breast, colorectal)</li><li><strong>MYC</strong>: Transcription factor (often amplified)</li></ul></blockquote><h3><strong>Variant Allele Fraction (VAF)</strong></h3><p>VAF = % of reads supporting the variant:</p><ul><li><strong>~50%</strong>: Heterozygous clonal mutation (early)</li><li><strong>~100%</strong>: Homozygous or LOH (loss of heterozygosity)</li><li><strong>5-40%</strong>: Subclonal mutation (late, heterogeneous)</li><li><strong><5%</strong>: Very low frequency (minor clone, sequencing noise)</li></ul><h3><strong>Sequencing Requirements</strong></h3><table><tr><th>Tumor Type</th><th>Coverage</th><th>Sensitivity</th></tr><tr><td><strong>WGS Tumor</strong></td><td>60-100X</td><td>Detect ~5% VAF variants</td></tr><tr><td><strong>WGS Normal</strong></td><td>30-40X</td><td>Filter germline</td></tr><tr><td><strong>WES Tumor</strong></td><td>200-300X</td><td>Higher depth for exons</td></tr><tr><td><strong>Liquid Biopsy</strong></td><td>1000-5000X</td><td>Ultra-deep for ctDNA</td></tr></table><h3><strong>Quality Metrics</strong></h3><ul><li><strong>Tumor Purity</strong>: % tumor cells (affects VAF interpretation)</li><li><strong>Ploidy</strong>: Average DNA copies per cell</li><li><strong>Contamination</strong>: Cross-sample contamination estimate</li><li><strong>Ti/Tv Ratio</strong>: ~2.5-3.0 for somatic variants</li><li><strong>Mutational Burden</strong>: Mutations per Mb (TMB)</li></ul><h3><strong>Filtering Strategies</strong></h3><p><strong>Panel of Normals (PoN)</strong>:</p><ul><li>Collection of normal samples processed identically</li><li>Filters recurrent technical artifacts</li><li>Removes germline variants in genes like olfactory receptors</li></ul><p><strong>Common Artifacts</strong>:</p><ul><li>FFPE artifacts (C>T transitions)</li><li>Oxidation artifacts (8-oxoG)</li><li>Alignment errors in homopolymers, STRs</li></ul><h3><strong>Clinical Actionability</strong></h3><p>OncoKB / CIViC annotation levels:</p><ul><li><strong>Level 1</strong>: FDA-approved drug for this mutation</li><li><strong>Level 2</strong>: Standard care biomarker</li><li><strong>Level 3</strong>: Clinical evidence (trials)</li><li><strong>Level 4</strong>: Preclinical evidence</li></ul><h3><strong>Example Actionable Mutations</strong></h3><table><tr><th>Gene</th><th>Mutation</th><th>Cancer</th><th>Therapy</th></tr><tr><td><strong>EGFR</strong></td><td>L858R, exon 19 del</td><td>NSCLC</td><td>Erlotinib, osimertinib</td></tr><tr><td><strong>BRAF</strong></td><td>V600E</td><td>Melanoma, CRC</td><td>Vemurafenib, dabrafenib</td></tr><tr><td><strong>KRAS</strong></td><td>G12C</td><td>Lung, CRC</td><td>Sotorasib, adagrasib</td></tr><tr><td><strong>HER2</strong></td><td>Amplification</td><td>Breast, gastric</td><td>Trastuzumab</td></tr><tr><td><strong>ALK</strong></td><td>Fusion</td><td>NSCLC</td><td>Crizotinib, alectinib</td></tr></table><h3><strong>Input Requirements</strong></h3><p>CSV samplesheet with columns:</p><ul><li><strong>patient</strong>: Patient ID</li><li><strong>sample</strong>: Sample ID (tumor, normal)</li><li><strong>fastq_1</strong>: Path to R1 FASTQ</li><li><strong>fastq_2</strong>: Path to R2 FASTQ</li><li><strong>status</strong>: 0 (normal) or 1 (tumor)</li></ul><h3><strong>Key Outputs</strong></h3><ul><li><strong>Somatic VCF</strong>: Tumor-specific variants</li><li><strong>Annotated VCF</strong>: With OncoKB, CIViC, COSMIC</li><li><strong>CNV Calls</strong>: Copy number alterations</li><li><strong>SV Calls</strong>: Structural variants, gene fusions</li><li><strong>Purity/Ploidy</strong>: Tumor characteristics</li><li><strong>MAF File</strong>: Mutation Annotation Format for visualization</li><li><strong>MultiQC Report</strong>: Comprehensive QC</li></ul><blockquote><p><strong>Perfect for:</strong> Precision oncology \u2022 Tumor profiling \u2022 Actionable mutations \u2022 Clinical trials \u2022 Drug resistance \u2022 Tumor evolution</p></blockquote>",
  "spec": [
    {
      "type": "Stash File",
      "label": "Sample Sheet",
      "name": "input",
      "description": "CSV with tumor-normal pairs",
      "required": true,
      "restrictions": {
        "allow_files": true,
        "allow_folders": false,
        "allowed_file_types": [
          ".csv"
        ]
      }
    },
    {
      "type": "Select",
      "label": "Reference Genome",
      "name": "genome",
      "description": "Reference genome",
      "defaultValue": "GRCh38",
      "required": true,
      "options": [
        {
          "label": "Human GRCh38",
          "value": "GRCh38"
        },
        {
          "label": "Human GRCh37",
          "value": "GRCh37"
        },
        {
          "label": "Mouse GRCm39",
          "value": "GRCm39"
        }
      ]
    },
    {
      "type": "Select",
      "label": "Somatic Variant Tools",
      "name": "tools",
      "description": "Somatic variant callers",
      "defaultValue": "mutect2,strelka,manta",
      "required": true,
      "options": [
        {
          "label": "Mutect2 + Strelka + Manta (Recommended)",
          "value": "mutect2,strelka,manta"
        },
        {
          "label": "Mutect2 Only",
          "value": "mutect2"
        },
        {
          "label": "Strelka + Manta",
          "value": "strelka,manta"
        },
        {
          "label": "All Somatic Callers",
          "value": "mutect2,strelka,manta,ascat,cnvkit"
        }
      ]
    },
    {
      "type": "Stash File",
      "label": "Output Directory",
      "name": "outdir",
      "description": "Output directory",
      "defaultValue": "./sarek-somatic-results",
      "required": true,
      "restrictions": {
        "allow_files": false,
        "allow_folders": true
      }
    }
  ],
  "jobConfig": [
    {
      "type": "Select",
      "label": "Compute Resources",
      "name": "system_size",
      "hidden": false,
      "options": [
        {
          "label": "XLARGE (Recommended for Tumor WGS)",
          "value": "xlarge",
          "mapValue": {
            "nodeSize": "XLARGE",
            "numNodes": 1,
            "withGpu": false
          }
        }
      ],
      "defaultValue": "xlarge"
    }
  ],
  "tags": [
    {
      "name": "variant-calling",
      "type": "field"
    },
    {
      "name": "somatic",
      "type": "task"
    },
    {
      "name": "cancer-genomics",
      "type": "task"
    }
  ]
}